BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31235660)

  • 1. Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology.
    Sechi E; Shosha E; Williams JP; Pittock SJ; Weinshenker BG; Keegan BM; Zalewski NL; Lopez-Chiriboga AS; Jitprapaikulsan J; Flanagan EP
    Neurology; 2019 Jul; 93(4):e414-e420. PubMed ID: 31235660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody.
    Dubey D; Pittock SJ; Krecke KN; Morris PP; Sechi E; Zalewski NL; Weinshenker BG; Shosha E; Lucchinetti CF; Fryer JP; Lopez-Chiriboga AS; Chen JC; Jitprapaikulsan J; McKeon A; Gadoth A; Keegan BM; Tillema JM; Naddaf E; Patterson MC; Messacar K; Tyler KL; Flanagan EP
    JAMA Neurol; 2019 Mar; 76(3):301-309. PubMed ID: 30575890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Clinical Outcomes of Transverse Myelitis Among Adults With Myelin Oligodendrocyte Glycoprotein Antibody vs Aquaporin-4 Antibody Disease.
    Mariano R; Messina S; Kumar K; Kuker W; Leite MI; Palace J
    JAMA Netw Open; 2019 Oct; 2(10):e1912732. PubMed ID: 31596489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.
    Mader S; Gredler V; Schanda K; Rostasy K; Dujmovic I; Pfaller K; Lutterotti A; Jarius S; Di Pauli F; Kuenz B; Ehling R; Hegen H; Deisenhammer F; Aboul-Enein F; Storch MK; Koson P; Drulovic J; Kristoferitsch W; Berger T; Reindl M
    J Neuroinflammation; 2011 Dec; 8():184. PubMed ID: 22204662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.
    van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ
    Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The frequency of longitudinally extensive transverse myelitis in MS: A population-based study.
    Asnafi S; Morris PP; Sechi E; Pittock SJ; Weinshenker BG; Palace J; Messina S; Flanagan EP
    Mult Scler Relat Disord; 2020 Jan; 37():101487. PubMed ID: 31707235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population-Based Incidence of Optic Neuritis in the Era of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies.
    Hassan MB; Stern C; Flanagan EP; Pittock SJ; Kunchok A; Foster RC; Jitprapaikulsan J; Hodge DO; Bhatti MT; Chen JJ
    Am J Ophthalmol; 2020 Dec; 220():110-114. PubMed ID: 32707199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MOG-IgG myelitis coexisting with systemic lupus erythematosus in the post-partum setting.
    Bilodeau PA; Kumar V; Rodriguez AE; Li CT; Sanchez-Alvarez C; Thanarajasingam U; Zalewski NL; Flanagan EP
    Mult Scler; 2020 Jul; 26(8):997-1000. PubMed ID: 31621483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and Varicella Zoster Virus Infection - Frequency of an Association.
    Di Pauli F; Morschewsky P; Berek K; Auer M; Bauer A; Berger T; Bsteh G; Rhomberg P; Schanda K; Zinganell A; Deisenhammer F; Reindl M; Hegen H
    Front Immunol; 2021; 12():769653. PubMed ID: 34737756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: Clinical and prognostic implications.
    Cobo-Calvo Á; Sepúlveda M; Bernard-Valnet R; Ruiz A; Brassat D; Martínez-Yélamos S; Saiz A; Marignier R
    Mult Scler; 2016 Mar; 22(3):312-9. PubMed ID: 26209592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4-IgG in Patients in the Optic Neuritis Treatment Trial.
    Chen JJ; Tobin WO; Majed M; Jitprapaikulsan J; Fryer JP; Leavitt JA; Flanagan EP; McKeon A; Pittock SJ
    JAMA Ophthalmol; 2018 Apr; 136(4):419-422. PubMed ID: 29470571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic resonance imaging in enterovirus-71, myelin oligodendrocyte glycoprotein antibody, aquaporin-4 antibody, and multiple sclerosis-associated myelitis in children.
    Tantsis EM; Prelog K; Alper G; Benson L; Gorman M; Lim M; Mohammad SS; Ramanathan S; Brilot F; Dale RC;
    Dev Med Child Neurol; 2019 Sep; 61(9):1108-1116. PubMed ID: 30537075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different magnetic resonance imaging features between MOG antibody- and AQP4 antibody-mediated disease: A Chinese cohort study.
    Chen C; Liu C; Fang L; Zou Y; Ruan H; Wang Y; Cui C; Sun X; Peng L; Qiu W
    J Neurol Sci; 2019 Oct; 405():116430. PubMed ID: 31465985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin-4 autoantibodies.
    Iorio R; Damato V; Mirabella M; Evoli A; Marti A; Plantone D; Frisullo G; Batocchi AP
    J Neurol; 2013 Sep; 260(9):2396-402. PubMed ID: 23793787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis.
    Jitprapaikulsan J; Chen JJ; Flanagan EP; Tobin WO; Fryer JP; Weinshenker BG; McKeon A; Lennon VA; Leavitt JA; Tillema JM; Lucchinetti C; Keegan BM; Kantarci O; Khanna C; Jenkins SM; Spears GM; Sagan J; Pittock SJ
    Ophthalmology; 2018 Oct; 125(10):1628-1637. PubMed ID: 29716788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of Aquaporin-4 Immunoglobulin G in Longitudinally Extensive Transverse Myelitis With Antiphospholipid Antibodies.
    Guerra H; Pittock SJ; Moder KG; Fryer JP; Gadoth A; Flanagan EP
    Mayo Clin Proc; 2018 Sep; 93(9):1299-1304. PubMed ID: 29655487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.